Overview

XBiotech is a fully integrated biosciences company dedicated to the discovery and development of therapeutic antibodies derived from natural human immunity

Nov 9, 2026 12:05 PM EST

Minimum 15 minutes delayed. Source: LSEG

Press Releases

View All
View All

Oct 23, 2026

XBiotech Announces Election of Sushma Shivaswamy and Jan-Paul Simard as Co-Chief Executive Officers
Read More
Read More
arrow icon arrow icon

Oct 19, 2026

XBiotech Announces Positive Phase II Final Efficacy Results from Investigator-Sponsored TASKIN Trial in Refractory Metastatic Colorectal Cancer
Read More
Read More
arrow icon arrow icon

Jun 15, 2026

XBiotech Launches Phase II Clinical Trial Evaluating Vilamakitug for the Treatment of Active Axial Spondyloarthritis
Read More
Read More
arrow icon arrow icon

Medicine should make you feel better, not worse

Modern medicine should help patients feel better, not worse. At XBiotech, we believe in the Hippocratic principle of "do no harm." We believe this is inherent to the innovative True Human™ antibody medicines we are developing. True Human™ antibodies move beyond the idea that effective medicines must come with toxicity or harmful side effects.

 

By utilizing the body’s natural immune system, XBiotech develops therapies that help you heal and feel better.

Contact Us
Contact Us

XBiotech’s True Human™ antibodies are derived from individuals with natural immunity to disease.

Extra links
Technology
Technology
Pipeline
Pipeline
Clinical
Clinical
News
News
About
About
Investor
Investor
Our contacts

Call:

(512) 386-2900 (512) 386-2900

Fax:

(512) 386-5505 (512) 386-5505
publicrelations@xbiotech.com publicrelations@xbiotech.com 5217 WINNEBAGO LN. AUSTIN 5217 WINNEBAGO LN. AUSTIN
Search
© XBiotech USA, INC. . All Rights Reserved 2026